NeuroOne CBO buys 33,333 shares at about $2
NeuroOne Medical Technologies’ chief business officer bought shares and received a new stock option grant, increasing his direct equity exposure to NMTC.
Rhea-AI Filing Summary
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Chief Business Officer David J. Wambeke reported two insider transactions. On August 27, 2026, he purchased 33,333 shares of common stock at a weighted average price of about $2.01 per share, with individual trade prices between $2.00 and $2.017, bringing his direct common share holdings to 199,999 shares. On August 28, 2026, he received a grant of 35,000 stock options with an exercise price of $1.77 per share, expiring on August 27, 2036; 25% of these options will vest on August 28, 2027 and the remaining 75% will vest in 12 equal quarterly installments. No Rule 10b5-1 trading plan is reported for these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 33,333 shares
Net Buy
2 txns
Insider
Wambeke David J.
Role
Chief Business Officer
Bought
33,333 shs ($67K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock F2 | 35,000 | $0.00 | $0.00 |
| Purchase | Common Stock F1 | 33,333 | $2.01 | $67K |
Holdings After Transaction:
Option to Purchase Common Stock — 35,000 contracts (Direct);
Common Stock — 199,999 shares (Direct)
Footnotes (2)
- F1. The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.
- F2. 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.
Key Figures
Common shares purchased: 33,333 shares
Weighted average purchase price: About $2.01 per share
Direct common shares after purchase: 199,999 shares
+5 more
8 metrics
Common shares purchased
33,333 shares
Open-market purchase on August 27, 2026
Weighted average purchase price
About $2.01 per share
Common stock purchase on August 27, 2026; individual prices from $2.00 to $2.017
Direct common shares after purchase
199,999 shares
Direct holdings following the August 27, 2026 purchase
Stock options granted
35,000 options
Grant on August 28, 2026 to acquire common stock
Option exercise price
$1.77 per share
Exercise price for 35,000 options granted August 28, 2026
Option expiration date
August 27, 2036
Expiration of 35,000 stock options
Initial vesting portion
25%
Portion of options vesting on August 28, 2027
Remaining vesting installments
12 quarterly installments
Schedule for vesting of remaining 75% of options
Key Terms
weighted average price, vest, quarterly installments
3 terms
weighted average price financial
"The price represents the weighted average price of the multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vest financial
"25% will vest on August 28, 2027, and the remaining 75% will vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
quarterly installments financial
"the remaining 75% will vest in 12 equal quarterly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock option grant did NMTC report for David J. Wambeke?
On August 28, 2026, David J. Wambeke received a grant of 35,000 stock options to acquire NeuroOne Medical Technologies common stock at an exercise price of $1.77 per share, with an expiration date of August 27, 2036.
What is the vesting schedule of David J. Wambeke’s new NMTC stock options?
For the 35,000 stock options granted on August 28, 2026, 25% will vest on August 28, 2027. The remaining 75% will vest in 12 equal quarterly installments thereafter, according to the disclosed vesting terms.
Were David J. Wambeke’s NMTC transactions made under a Rule 10b5-1 trading plan?
No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with these transactions by David J. Wambeke in NeuroOne Medical Technologies stock and options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
